Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Characterization of a novel Pde6b-deficient rat model of retinal degeneration and treatment with adeno-associated virus (AAV) gene therapy

Abstract

In humans, mutations in the beta subunit of cGMP-phosphodiesterase type 6 (PDE6B) cause autosomal recessive retinitis pigmentosa (RP), which typically has an aggressive clinical course of early-onset severe vision loss due to rapid photoreceptor degeneration. In this study, we describe the generation of a novel Pde6b-deficient rat model using CRISPR-Cas9 genome editing. We characterize the model at multiple time points using clinical imaging modalities as well as histology with immunohistochemistry to show rapid photoreceptor degeneration compared to wild-type and heterozygous animals. We describe the manufacture of two different adeno-associated viral (AAV) vectors (AAV2/1, AAV2/5) under current Good Manufacturing Practices (cGMP) and demonstrate their ability to drive human PDE6B expression in vivo. We further demonstrate the ability of AAV-mediated subretinal gene therapy to delay photoreceptor loss in Pde6b-deficient rats compared to untreated controls. However, severe progressive photoreceptor loss was noted even in treated eyes, likely due to the aggressive nature of the disease. These data provide useful preclinical data to guide the development of potential human gene therapy for PDE6B-associated RP. In addition, the rapid photoreceptor degeneration of the Pde6b-deficient rat with intact inner retina may provide a useful model for the study of cell replacement strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic of CRISPR-Cas9 targeting strategy and immunohistochemical and immunoblot demonstration of complete ablation of Pde6b protein expression in Pde6b knockout animals.
Fig. 2: Loss of Pde6b causes severe thinning of the outer nuclear layer due to extensive photoreceptor cell loss.
Fig. 3: Subretinal delivery using two different serotypes of AAV (AAV1 and AAV5) drives human PDE6B in vivo.
Fig. 4: Gene augmentation using AAV1 delays photoreceptor loss to a larger degree than AAV5.

Similar content being viewed by others

Data availability

All pertinent data generated and analyzed during this study can be found within the published manuscript and supplementary data file.

References

  1. McLaughlin ME, Sandberg MA, Berson EL, Dryja TP. Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat Genet. 1993;4:130–4.

    Article  CAS  PubMed  Google Scholar 

  2. Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124:1314–31.

    Article  PubMed  Google Scholar 

  3. McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP. Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci USA. 1995;92:3249–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kuehlewein L, Zobor D, Stingl K, Kempf M, Nasser F, Bernd A, et al. Clinical phenotype of PDE6B-associated retinitis pigmentosa. Int J Mol Sci. 2021;22:2374.

  5. Kim YN, Song JS, Oh SH, Kim YJ, Yoon YH, Seo EJ, et al. Clinical characteristics and disease progression of retinitis pigmentosa associated with PDE6B mutations in Korean patients. Sci Rep. 2020;10:19540.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature. 1990;347:677–80.

    Article  CAS  PubMed  Google Scholar 

  7. Nishiguchi KM, Carvalho LS, Rizzi M, Powell K, Holthaus SM, Azam SA, et al. Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179. Nat Commun. 2015;6:6006.

    Article  CAS  PubMed  Google Scholar 

  8. Tucker BA, Burnight ER, Cranston CM, Ulferts MJ, Luse MA, Westfall T, et al. Development and biological characterization of a clinical gene transfer vector for the treatment of MAK-associated retinitis pigmentosa. Gene Ther. 2022;29:259–88.

  9. Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, et al. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm. 2014;11:1591–8.

    Article  CAS  PubMed  Google Scholar 

  10. Yang JM, Chung S, Yun K, Kim B, So S, Kang S, et al. Long-term effects of human induced pluripotent stem cell-derived retinal cell transplantation in Pde6b knockout rats. Exp Mol Med. 2021;53:631–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Han IC, Burnight ER, Ulferts MJ, Worthington KS, Russell SR, Sohn EH, et al. Helper-dependent adenovirus transduces the human and rat retina but elicits an inflammatory reaction when delivered subretinally in rats. Hum Gene Ther. 2019;30:1371–84.

  12. Han IC, Cheng JL, Burnight ER, Ralston CL, Fick JL, Thomsen GJ, et al. Retinal tropism and transduction of adeno-associated virus varies by serotype and route of delivery (intravitreal, subretinal, or suprachoroidal) in rats. Hum Gene Ther. 2020;31:1288–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wiley LA, Burnight ER, Drack AV, Banach BB, Ochoa D, Cranston CM, et al. Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration. Hum Gene Ther. 2016;27:835–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Han IC, Burnight ER, Kaalberg EE, Boyce TM, Stone EM, Fingert JH, et al. Chimeric helper-dependent adenoviruses transduce retinal ganglion cells and muller cells in human retinal explants. J Ocul Pharmacol Ther. 2021;37:575–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.

    Article  CAS  PubMed  Google Scholar 

  16. Yeo JH, Jung BK, Lee H, Baek IJ, Sung YH, Shin HS, et al. Development of a Pde6b gene knockout rat model for studies of degenerative retinal diseases. Invest Ophthalmol Vis Sci. 2019;60:1519–26.

    Article  CAS  PubMed  Google Scholar 

  17. Wiley LA, Burnight ER, Kaalberg EE, Jiao C, Riker MJ, Halder JA, et al. Assessment of adeno-associated virus serotype tropism in human retinal explants. Hum Gene Ther. 2018;29:424–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jomary C, Vincent KA, Grist J, Neal MJ, Jones SE. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther. 1997;4:683–90.

    Article  CAS  PubMed  Google Scholar 

  19. Bennett J, Tanabe T, Sun D, Zeng Y, Kjeldbye H, Gouras P, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med. 1996;2:649–54.

    Article  CAS  PubMed  Google Scholar 

  20. Thompson JR, Worthington KS, Green BJ, Mullin NK, Jiao C, Kaalberg EE, et al. Two-photon polymerized poly(caprolactone) retinal cell delivery scaffolds and their systemic and retinal biocompatibility. Acta Biomater. 2019;94:204–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Giacalone JC, Wiley LA, Burnight ER, Songstad AE, Mullins RF, Stone EM, et al. Concise review: patient-specific stem cells to interrogate inherited eye disease. Stem Cells Transl Med. 2016;5:132–40.

    Article  PubMed  Google Scholar 

  22. Wiley LA, Burnight ER, Songstad AE, Drack AV, Mullins RF, Stone EM, et al. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog Retin Eye Res. 2015;44:15–35.

    Article  PubMed  Google Scholar 

  23. Wiley LA, Burnight ER, DeLuca AP, Anfinson KR, Cranston CM, Kaalberg EE, et al. cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness. Sci Rep. 2016;6:30742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

University of Iowa Institute for Vision Research, University of Iowa, Iowa City, Iowa; Research to Prevent Blindness, New York City, New York; Carver cGMP Operational Endowment for Gene Therapy, University of Iowa, Iowa City, Iowa; National Institutes of Health Grant (NIH; Bethesda, MD, USA): P30 EY025580.

Author information

Authors and Affiliations

Authors

Contributions

ICH and LAW conceived of, designed, performed experiments, analyzed data and wrote the manuscript. ICH, LAW, DO, MJL, BEH and KMS acquired samples and helped perform experiments. EMS and RFM provided funding support, edited and approved the final manuscript. BAT conceived the study, provided funding support, as well as edited and approved the final manuscript.

Corresponding author

Correspondence to Budd A. Tucker.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

As also stated in the methods section, all rat experiments were conducted with the approval of the University of Iowa Animal Care and Use Committee (Animal welfare assurance #1031317) and were consistent with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, I.C., Wiley, L.A., Ochoa, D. et al. Characterization of a novel Pde6b-deficient rat model of retinal degeneration and treatment with adeno-associated virus (AAV) gene therapy. Gene Ther 30, 362–368 (2023). https://doi.org/10.1038/s41434-022-00365-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-022-00365-y

This article is cited by

Search

Quick links